Clay Siegall: The Driving Force behind Seattle Genetics

Seattle Genetics is a facility that we have witnessed rise from an ordinary research establishment to being among the top players in the cancer research world. The research center is currently the first one to successfully develop and get FDA approval for more than 20 cancer antibody conjugates. All these successes can be thanked to Dr. Clay Siegall who is the founder of the facility. In a recent interview by Inspirery, Siegall says that he has always been interested in medicine and technology, but his concern in cancer was sparked off when one of his family members got the disease, and there was no mode of treatment suitable for them. Chemo and other radical surgery only went on to worsen the condition of Clay’s relative. That is when he decided to find better alternatives for cancer treatment and also make a living from the same. According to the interview, Seattle Genetics took almost a decade before it could bring in profits and today its main source of money is through drug sales. However, they not all drugs always get approved by the FDA. The facility gets its customers through salespeople who market its products and to make it even better, Clay reveals that they have an excellent legal team which helps them get business deals and partnerships. According to him, hard work, passion and being focused are the secret ingredients to his success.

About Clay Siegall

Apart from being the founder and chief executive officer of Seattle Genetics, Clay Siegall occupies other senior positions in prominent companies in the health industry such as being director of Ultragenyx and Alder Biopharmaceuticals, and he once worked at Bristol-Myers Squibb pharmaceutical for seven years and the national institutes of health for two years. He is also well educated and is a graduate of the University of Maryland where he got a B.S in zoology and George Washington University from where he received his Ph.D. in Genetics. He has helped Seattle genetics grow to be one of the biggest biopharmaceuticals in the United States, and there are no rooms for setbacks which is proved by the string of cancer conjugates that the research center has developed.